Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Predictive cytokine biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis.
Th1, Th2 and Th17 Cytokine Profile in Patients with Multiple Sclerosis Following Treatment with Rapamycin.
US health insurance is an obstacle to disease-modifying treatments in MS.
A novel highly selective 5-HT6 receptor antagonist attenuates ethanol and nicotine seeking but does not affect inhibitory response control in Wistar rats.
Hereditary and metabolic myelopathies.
Pembrolizumab-Induced Demyelinating Polyradiculoneuropathy.
Functional Brain Network Alterations in Clinically Isolated Syndrome and Multiple Sclerosis: A Graph-based Connectome Study.
Monoclonal Antibody Therapy for Neuromyelitis Optica Spectrum Disorder: Current and Future.
Comparison of Personal Resources in Patients Who Differently Estimate the Impact of Multiple Sclerosis.
Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis?
Sparing of tissue by using micro-slit-beam radiation therapy reduces neurotoxicity compared with broad-beam radiation therapy.
A Microsoft Kinect-Based Point-of-Care Gait Assessment Framework for Multiple Sclerosis Patients.
Oligodendrocyte Injury and Pathogenesis of HIV-1-Associated Neurocognitive Disorders.
Drinking away fatigue in multiple sclerosis.
Is There an Increased Risk for Ischemic Stroke in Patients with Multiple Sclerosis, and If So, Should Preventive Treatment Be Considered?
Prediction of Adiposity by Body Mass Index in Patients With Multiple Sclerosis.
Evaluation of the Expanded Disability Status Scale and the Multiple Sclerosis Functional Composite as clinical endpoints in multiple sclerosis clinical trials: quantitative meta-analyses.
Guillain Barré Syndrome, Systemic Lupus Erythematosus and Acute Intermittent Porphyria - A Deadly Trio.
HIV-1 Tat Inhibits Autotaxin Lysophospholipase D Activity and Modulates Oligodendrocyte Differentiation.
Corrigendum.
Cognitive impairment and magnetic resonance imaging correlates in primary progressive multiple sclerosis.
Atypical parkinsonism in C9orf72 expansions: a case report and systematic review of 45 cases from the literature.
The MS Center of Saint Louis: a practice perspective of the impacts of high cost sharing.
IL-10 Modulates Th17 Pathogenicity during Autoimmune Diseases.
Ballroom Dance for Persons with Multiple Sclerosis: Physical and Cognitive Efficacy: 2997 Board #62 June 3, 3: 30 PM - 5: 00 PM.
Pages
« first
‹ previous
…
794
795
796
797
798
799
800
801
802
…
next ›
last »